What is Initial Deployment

The lifecycle of online services comprise four phases. In the research and development phase the requirements for a service are analysed, the technical options are reviewed, and a prototype system is developed. In the market validation phase the prototype is further developed into a pre-production system and the market potential for the service is processed into a business plan. If financial resources are found to translate the business plan into a sustainable service, an initial deployment phase provides a transition period in which the service is available and is fully functional but needs to build up a market share to become self-supporting or profitable. The final phase is the full deployment phase in which the service is cost neutral or profitable. The latter depends on the initial business objectives of the consortium which carried forward the business plan.

Participate to TENALEA Initial Deployment

The TENALEA Initial Deployment will continue until 1 may 2010. Until the end of 2008, the focus will be on Academic clinical trials groups. After 2008, the services will also be offered to commercial users , such as the Contract Research Organisations and the pharmaceutical and equipment manufacturing industry.

 During the initial deployment period, the TENALEA Initial Deployment consortium is financially supported by the European Union to assist individual institutes and organisations to take up TENALEA clinical trials data management services for the trials these groups conduct.

Although this phase is focusing on take-up of the services, participating individuals and entities are invited to contribute to further improvement and extension of the service portfolio. This process is supported by an open forum structure, where each user can send contributions and request, and read ongoing requests.

The TENALEA Initial Deployment consortium invites Clinical Trial Coordination Centers and clinical trial principal investigators to participate to the Initial Deployment of the TENALEA Service portfolio. Participation to TENALEA has major benefits:

• Affordable - and for qualifying institutions even free - use of online services for randomisation in clinical trials
• Reliable - TENALEA provides services which have been in use for over a decade by major clinical trial coordination centres
• Simple - all services are provided over the Internet, and no local installation is required
• Industry grade services based on Service Level Agreements, with guaranteed service availability
• Secure - all systems are protected by two stage firewalls, and traffic in transit is being encrypted
• Trans European Network - a European deployment support network with support centers in France, Germany, United Kingdom, Poland and the Netherlands

Clinical trial principal investigators

Clinical trial principal investigators may streamline their clinical trials process by adopting TENALEA services. To initiate your participation today, complete the participation request form for principal investigators.

Clinical Trial principal investigator inquiry form

Clinical trial coordination centers

Clinical trial coordination centers can benefit from TENALEA services to improve their existing process. To initiate participation today, complete the participation request form for principal investigators.

 Clinical trial coordination center inquiry form

Contract Research Organisations

Until the end of 2008, CRO's are invited to participate to further develop the business model for shared service provision to this target group. The TENALEA Initial Deployment consortium includes a pharmaceutical industry to manage these contributions. One of the main challenges here is to provide the service level required for this target groups. The TENALEA Initial Deployment project has several tasks in its project plan that address these challenges. CRO's may complete the CRO inquiry form to obtain more information, or to be contacted by project staff.

CRO Inquiry form

pharmaceutical- and equipment manufacturing- industry

The pharmaceutical industry and equipment manufacturing industry are not directly addressed until the end of 2008. Until this date, industry representatives are invited to participate to further develop the business model for shared service provision to this target group. The TENALEA Initial Deployment consortium includes a pharmaceutical industry to manage these contributions. One of the main challenges here is to provide the service level required for this target groups. The TENALEA Initial Deployment project has several tasks in its project plan that address these challenges. CRO's may complete the CRO inquiry form to obtain more information, or to be contacted by project staff.

industry inquiry form